Â鶹ŮÓÅ

We are doctors who trained continents apart: one of us in Sweden (Peterson) and one in India (Pai). As we worked during the 1980s and ’90s in those disparate countries, neither of us ever saw a case of measles, diphtheria, or whooping cough. That was not a fluke. It was because the world once chose to fight these deadly childhood infections with miraculous tools called vaccines. (Stefan Swartling Peterson and Madhukar Pai, 11/12)

Naming veteran regulator Richard Pazdur to head the Food and Drug Administration’s Center for Drug Evaluation and Research is fantastic news for patients, drug companies, and anyone who cares about a rigorous, data-based FDA. (Matthew Herper, 11/11)

These labeling revisions signal a meaningful shift toward more nuanced, evidence-based communication of hormone therapy risks—one that prioritizes clinical relevance, distinguishes between different formulations and patient populations, and balances the narrative to reflect both safety and therapeutic value. It may also reduce the outsized fear that has prevented approximately 50 million women from the short- and long-term health benefits of this therapy. If implemented, these changes may guide appropriately tailored hormone therapy use and optimize individualized care. (FDA Commissioner Martin A. Makary, Christine P. Nguyen, and Tracy Beth Høeg, et al, 11/10)

Abortion pills have prevented Dobbs from unleashing all the ill effects that many people feared. But as threats to the pills’ availability grow, it would be a mistake if the surprising trends of the last three years led to complacency. (11/12)

Hundreds of foreign medical professionals work in Massachusetts with an H-1B visa. Now those work permits will cost $100,000. (11/12)

It quickly emerged that Trump may not actually send out payments, certainly not anytime soon. (11/11)